Active Watch List: The Walt Disney Company (NYSE:DIS), Pfizer Inc. (NYSE:PFE), JinkoSolar Holding Co., Ltd. (NYSE:JKS), Concert Pharmaceuticals (NASDAQ:CNCE), ITT Corporation (NYSE:ITT)

The Walt Disney Company (NYSE:DIS) in South East Asia (SEA) on 10 October announced changes to its management team to position for rapid growth in the film and media distribution landscape in the region. Amit Malhotra, previously General Manager Disney Media Distribution and Media+ becomes General Manager, Studio Entertainment SEA and will oversee all the Studio businesses (Theatrical, In-Home, Live Events and Stage Plays) in Southeast Asia. The Walt Disney Company (NYSE:DIS) belongs to Services sector. Its net profit margin is 15.40% and weekly performance is -5.25%. On last trading day company shares ended up $83.91. The Walt Disney Company (NYSE:DIS) distance from 50-day simple moving average (SMA50) is -5.59%.

Pfizer Inc. (NYSE:PFE) said Monday that its experimental breast-cancer treatment, palbociclib, has been granted priority review by the U.S. Food and Drug Administration, potentially speeding the approval process by up to four months. Pfizer Inc. (NYSE:PFE) shares fell -2.27% in last trading session and ended the day at $28.47. PFE Gross Margin is 81.30% and its return on assets is 17.20%. Pfizer Inc. (NYSE:PFE) quarterly performance is -6.38%.

JinkoSolar Holding Co., Ltd. (NYSE:JKS), a global leader in the PV industry, announced that it will supply 21.5MW PV solar modules for the construction of the Searchlight solar project located near Searchlight, NV, approximately 50 miles south of Las Vegas. On 13 October, JinkoSolar Holding Co., Ltd. (NYSE:JKS) shares moved down -6.65% and was closed at $21.32. JKS EPS growth in last 5 year was -11.10%. JinkoSolar Holding Co., Ltd. (NYSE:JKS) year to date (YTD) performance is -27.24%.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced Phase 1 data of CTP-354, a novel, potentially first-in-class, non-sedating, once-daily oral treatment for spasticity. In this multiple ascending dose trial, no sedation or ataxia was observed with CTP-354 and the drug was generally well tolerated across all dose cohorts. The Company will be presenting these findings today during a poster session at the American Neurological Association’s Annual Meeting in Baltimore, Maryland. Concert expects to initiate a Phase 2 clinical trial evaluating CTP-354 in patients with spasticity associated with spinal cord injury by the end of 2014. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) ended the last trading day at $11.96. Company weekly volatility is calculated as 5.26% and price to cash ratio as 2.19. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) showed a weekly performance of -8.00%.

ITT Corporation (NYSE:ITT) announced a quarterly dividend on Thursday, October 9th, reports. Investors of record on Friday, December 12th will be paid a dividend of 0.11 per share on Thursday, December 31st. This represents a $0.44 annualized dividend and a dividend yield of 1.08%. The ex-dividend date is Wednesday, December 10th. ITT Corporation (NYSE:ITT) shares fell -2.70% in last trading session and ended the day at $38.63. ITT Gross Margin is 32.10% and its return on assets is 13.50%. ITT Corporation (NYSE:ITT) quarterly performance is -17.95%.